Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthSource vs MadeMed

By GLP-1 ScorecardUpdated

HealthSourceFactor scores not reassessed.
Site position #104

Lower score

MadeMed
Site position #35

Higher score

Score comparison

MadeMed has the higher recorded score — 80.4/100 to 71.2/100.

MadeMed grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MadeMed advertises all-dose pricing across 30-, 90- and 360-day purchases, with a consultation-fee conflict to resolve before prepaying.

Before you choose

Before comparing the headline prices, the HealthSource review and the MadeMed review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, HealthSource vs Mevo Health and Human+ vs MadeMed compare each of them with another graded program, and the list of alternatives to HealthSource ranks the programs closest to HealthSource on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueMadeMed +8
66
74
Dose & formulationMadeMed +7
83
90
Clinical oversightMadeMed +4
80
84
Labs & monitoringMadeMed +8
54
62
FulfillmentMadeMed +10
80
90
Contract termsMadeMed +33
55
88
HealthSource · top barMadeMed · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricHealthSourceMadeMed
WeighScore71.2/10080.4/100
GradeCB−
Site position#104#35
SemaglutideFull Dose: $199 every 4 weeks; other selections vary$179 every 30 days; $483/90 days or $1,718/360 days ($143.17 equivalent per 30 days); consultation fees and usable supply require confirmation
TirzepatideFull Dose: $299 every 4 weeks; other selections varyInjection or sublingual: $249 every 30 days; $672/90 days or $2,390/360 days ($199.17 equivalent per 30 days); final fees and supply unverified
CoverageConfirm treatment eligibility by stateConfirm selected treatment/state: sublingual tirzepatide FAQ lists 40 states; current injection-state map unverified
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
HealthSource

Site position #104 · C

Factor scores not reassessed.

Strengths

  • Separate starting supply choices are visible on the product pages
  • The site advertises ongoing telehealth and physician messaging
  • Publishes prescription and subscription cancellation policies

What to consider

  • The displayed price depends on the supply choice
  • Confirm how the advertised reassessment refund works with the general policy
  • An assigned pharmacy and state eligibility need confirmation
MadeMed

Site position #35 · B−

Strengths

  • Public selectors show full charges for 30-, 90- and 360-day plans across the listed GLP-1 products
  • Advertises the same pricing across doses, ongoing clinical messaging and included injection supplies
  • Current terms name MDI Medical Group PC and four partner pharmacy brands
  • A 30-day purchase is advertised alongside the larger prepaid options

What to consider

  • Lowest advertised equivalents require $1,718/$2,390 360-day billing plans; terms reject prorated refunds
  • Product pages list $20/$30 consultation fees while How It Works says consultation is included and ineligible payments are refunded in full
  • The forty-state claim is specific to sublingual tirzepatide; an injection-state map was not established
  • Assigned clinician/pharmacy branch, patient lab costs, final first debit and usable prescription supply remain unresolved

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard